https://www.selleckchem.com/pr....oducts/resiquimod.ht
COVID-19 convalescent plasma (CCP) is widely used as a treatment. While safety data are enough, high-level evidences of efficacy are still missing. We summarize here the results from randomized controlled trials (RCT) published to date and analyze their flaws and biases. We then provide suggestions for next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.The relentless spread of coronavirus disease 2019 (COVID-19) and its penetration into the least develop
Mi piace
Commento
Condividi
